Cognizance Biomarkers Overview

  • Founded
  • 2012
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Cognizance Biomarkers General Information

Description

Operator of a neurology and neuroinflammation-focused diagnostics company intended to achieve leadership in proteomic and genomic-based testing for improved diagnosis and treatment of neurological disorders, offering rapid, accurate and cost-effective precision medicine solutions for optimal patient outcomes. The company's diagnostic test identifies molecules that are indicative of these inflammation-induced seizures, enabling doctors to diagnose and treat people with non-epileptic seizures.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Biotechnology
Acquirer
Primary Office
  • 3160 Chestnut Street
  • Suite 200
  • Philadelphia, PA 19104
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cognizance Biomarkers Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 01-Jan-2015 Completed Startup
3. Grant 01-Jan-2015 00000 Completed Startup
2. Accelerator/Incubator 09-Apr-2013 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Cognizance Biomarkers’s complete valuation and funding history, request access »

Cognizance Biomarkers Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Science Center Accelerator/Incubator Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
UPstart Accelerator/Incubator Minority 000 0000 000000 0
To view Cognizance Biomarkers’s complete investors history, request access »